Diagnosis of MDS, or a clinical suspicion for a new diagnosis of MDS, for whom routine diagnostic testing is requested or planned to be requested.
Seen in the outpatient setting.
Not been previously treated with disease-modifying therapy (such as lenalidomide or hypomethylating agents).
Note: Patients who have received transfusional support, erythropoietin-stimulating agents, growth factor support, or luspatercept are eligible.
At least 18 years of age.
Able to understand and willing to sign an IRB approved written informed consent document.
Treating physician at Washington University School of Medicine who directs therapy for individuals with hematologic malignancies.
Able and willing to complete standardized questionnaires about stakeholder perceptions of ChromoSeq during the ChromoSeq implementation process. (Written documentation of informed consent is not required.)
You may not be if
Younger than 18 years of age
Does not treat patients at Washington University School of Medicine
Clareo Health | Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
